Streetbeat News

JYNT

The Joint Corp.

https://www.thejoint.com

Industry

Medical - Care Facilities

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

The Joint Corp. projects FY24 system-wide sales to be between $530M-$545M, with system-wide comparable sales for clinics open 13+ months expected to be in the 4%-mid single digits range. The company also anticipates opening 60-75 new franchised clinics, excluding the impact of refranchised clinics.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 10:15 pm

Joint (NASDAQ:JYNT) reported Q4 2023 GAAP EPS of $(0.750), missing the $0.010 estimate by 7600%, with sales of $30.614M beating the $29.082M estimate by 5.27%. This represents a 10.07% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 10:05 pm

Numerous companies are scheduled to report their quarterly earnings on March 7, 2024, with a mix of projected earnings and losses across various sectors. Notable mentions include CI&T, Stevanato Gr, ABM Industries, Bilibili, BJ's Wholesale Club, Burlington Stores, and many others, indicating a significant day for investors to monitor potential market movements.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:49 am

Wynn Resorts, Limited (NASDAQ:WYNN) shares dropped by 8.1% despite reporting higher than expected third-quarter revenue and earnings per share. The company's revenue was $1.67 billion, surpassing the consensus estimate of $1.585 billion, and adjusted EPS was 99 cents, beating the estimate of 75 cents. The article also lists other stocks that moved in the mid-day session, with various companies experiencing significant gains or losses after reporting their financial results, guidance updates, or other corporate actions.

Portfolio Pulse from Lisa Levin

November 10, 2023 | 6:34 pm

Joint (NASDAQ:JYNT) reported its Q3 earnings, missing estimated earnings by 350.0% with an EPS of $-0.05 versus an estimate of $0.02. However, revenue was up $2.87 million from the same period last year. Last quarter, the company also missed on EPS by $0.02, which was followed by a 3.64% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 9:45 pm

Joint Corp (NASDAQ:JYNT) reported Q3 losses of $(0.05) per share, missing the analyst consensus estimate of $0.02 by 350 percent. This is a 266.67 percent decrease from the same period last year. However, the company reported quarterly sales of $29.47 million, beating the analyst consensus estimate of $29.06 million by 1.42 percent, a 10.79 percent increase from last year.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 9:40 pm

On Tuesday, 132 companies hit new 52-week lows. Among them, Corning (NYSE:GLW) was the largest in terms of market cap, while Wheeler Real Estate IT (NASDAQ:WHLR) was the smallest. Fortress Biotech (NASDAQ:FBIO) saw the largest move with shares plummeting 1350.03%, while Insulet (NASDAQ:PODD) made the biggest bounce back, moving up 0.0% shortly after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 5:09 pm

Roth MKM analyst George Kelly maintains a 'Buy' rating on Joint (NASDAQ:JYNT) but has lowered the price target from $16 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:58 pm

Several healthcare stocks experienced significant movement in Wednesday's after-market session. Notable gainers included Infinity Pharmaceuticals (INFI), TransCode Therapeutics (RNAZ), Longeveron Inc. - Subscription Right (LGVNR), Scinai Immunotherapeutics (SCNI), Avalo Therapeutics (AVTX), and NanoString Technologies (NSTG). On the other hand, Kiromic BioPharma (KRBP), OKYO Pharma (OKYO), Bionomics (BNOX), Impel Pharmaceuticals (IMPL), Creative Medical Tech (CELZ), and Joint (JYNT) saw declines.

Portfolio Pulse from Benzinga Insights

September 13, 2023 | 9:31 pm

The Joint Corp. has reduced its FY23 revenue outlook from $123M-$128M to $115M-$118M, which is below the estimated $123.94M.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 9:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.